Exelixis to Co-Host Investor/Media Briefing to Discuss Data Presented at the ESMO 2017 Congress
September 06 2017 - 5:23PM
Business Wire
-- Presentation to be webcast on
www.exelixis.com --
Exelixis, Inc. (NASDAQ: EXEL) today announced that the company,
along with its partner Ipsen, will host a live briefing event for
investors and media to discuss data for cabozantinib presented at
the European Society for Medical Oncology (ESMO) 2017 Congress. The
webcast event will be held on Sunday, September 10, 2017, beginning
at 18:45 CEST (local Madrid time) / 12:45 p.m. EDT / 9:45 a.m.
PDT.
During the briefing, Exelixis and Ipsen management and invited
guests will discuss and provide context for clinical data for
cabozantinib presented at the ESMO 2017 Congress. Exelixis
previously announced that cabozantinib will be the subject of eight
presentations at the meeting, including a poster discussion on
CABOSUN highlighting the progression-free survival analysis by the
independent radiology review committee and updated overall survival
results. CABOSUN is a phase 2 trial of cabozantinib compared with
sunitinib in patients with previously untreated advanced renal cell
carcinoma. Updated data from the phase 1 trial evaluating the
combination of cabozantinib and nivolumab with or without
ipilimumab in patients with metastatic urothelial carcinoma and
other genitourinary tumors will be the subject of an oral
presentation.
The briefing webcast may be accessed via the Event Calendar page
under Investors & Media at www.exelixis.com. Please connect to
the company’s website at least 15 minutes prior to the presentation
to ensure adequate time for any software download that may be
required to listen to the webcast. Alternatively, please call (855)
793-2457 (domestic) or (631) 485-4921 (international) and provide
the conference call passcode 68961937 to join by phone.
A telephone replay will be available until 11:59 p.m. EDT on
September 17, 2017. Access numbers for the telephone replay are:
855-859-2056 (domestic) and 404-537-3406 (international); the
passcode is 68961937. A webcast replay will also be available
archived on www.exelixis.com for one year.
About Exelixis
Exelixis, Inc. (Nasdaq: EXEL) is a biopharmaceutical company
committed to the discovery, development and commercialization of
new medicines to improve care and outcomes for people with cancer.
Since its founding in 1994, three products discovered at Exelixis
have progressed through clinical development, received regulatory
approval, and entered the marketplace. Two are derived from
cabozantinib, an inhibitor of multiple tyrosine kinases including
MET, AXL and VEGF receptors: CABOMETYX® tablets approved for
previously treated advanced kidney cancer and COMETRIQ® capsules
approved for progressive, metastatic medullary thyroid cancer. The
third product, COTELLIC®, is a formulation of cobimetinib, a
reversible inhibitor of MEK, is marketed under a collaboration with
Genentech (a member of the Roche Group), and is approved as part of
a combination regimen to treat advanced melanoma. Both cabozantinib
and cobimetinib have shown potential in a variety of forms of
cancer and are the subjects of broad clinical development programs.
For more information on Exelixis, please visit www.exelixis.com or
follow @ExelixisInc on Twitter.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170906006789/en/
Exelixis, Inc.Susan Hubbard, 650-837-8194EVP, Public Affairs and
Investor Relationsshubbard@exelixis.comorFor Exelixis, Inc.Hal
Mackins, 415-994-0040hal@torchcomllc.com
Exelixis (NASDAQ:EXEL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Exelixis (NASDAQ:EXEL)
Historical Stock Chart
From Apr 2023 to Apr 2024